Figure 9.
A timeline of the clinical approval and major decisions regarding EGFR targeting TKIs (gefitinib in blue, erlotinib in green, afatinib in red, and osimertinib in gray).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.